Company News »

OPKO Announces 4Kscore(R) Abstracts at the 2015 American Urological Association (AUA) Annual Meeting

Business Wire
Share on StockTwits
Published on

OPKO Health, Inc. (NYSE:OPK) today announced six important new clinical trial results pertaining to the 4Kscore(R) test presented at the 2015 American Urological Association (AUA) annual meeting, May 15 to May 19, 2015, in New Orleans.

Date and time, title and location of the 4Kscore presentations at the New Orleans Morial Convention Center (NOMCC):

Friday, May 15, 1:00 pm – Moderated poster MP6-04: The 4Kscore Test predicts high-grade prostate cancer on biopsy with PSA less than 4 ng/mL; NOMCC #220-221

Sunday May 17, 11:10 am – Urologic Oncology Forum podium presentation: Screening for lethal prostate cancer using PSA and related blood biomarkers; NOMCC #356-357

Sunday May 17, 12:50 am – Urologic Oncology Forum podium presentation: Use of commercial blood biomarkers to identify risk of aggressive prostate cancer; NOMCC #356-357

Monday, May 18, 8:00 am – Moderated poster MP60-06: The performance of the 4Kscore for predicting high-grade cancer on biopsy of the prostate does not depend on the age of the patient; NOMCC #206-207

Monday May 18, 10:30 am – Podium presentation PD38-03: The 4Kscore is associated with more advanced disease at radical prostatectomy; Results from a multi-Institutional prospective trial; NOMCC #215-216

Tuesday, May 19, 8:00 am – Moderated poster MP77-20: Among men with low-grade prostate cancer on prostate biopsy, the 4Kscore predicts more aggressive prostate cancer at prostatectomy; NOMCC 228-230

In addition to the regular AUA program presentations, the OPKO 4Kscore test will also be featured on Tuesday May 19th in an industry program titled “Biomarkers and Genomic Testing in Prostate Cancer: Integration Into Clinical Practice” from 10:00 – 11:00 am at NOMCC Science and Technology Hall #1043

About the 4Kscore Test

The 4Kscore is the only blood test that accurately identifies risk for aggressive prostate cancer. The 4Kscore measures the blood levels of four different prostate-derived kallikrein proteins: Total PSA, Free PSA, Intact PSA and Human Kallikrein-2 (hK2). These biomarkers are combined with a patient’s age, Digital Rectal Exam (DRE) status (nodule / no nodule), and prior negative biopsy status (yes / no) using a proprietary algorithm to calculate the risk (probability) of finding a Gleason Score 7 or higher prostate cancer. The four kallikrein panel of biomarkers utilized in the 4Kscore Test is based on over a decade of research conducted by scientists at Memorial Sloan-Kettering Cancer Center and leading European institutions. The 4Kscore Test provides individualized risk for the presence of aggressive prostate cancer and adds new information to the shared decision making discussion between a Urologist and patient.

About OPKO Health

OPKO is a multinational biopharmaceutical and diagnostics company that seeks to establish industry-leading positions in large, rapidly growing markets by leveraging its discovery, development and commercialization expertise and novel and proprietary technologies. For more information, visit http://www.opko.com.

SAFE HARBOR STATEMENT

This press release contains “forward-looking statements,” as that term is defined under the Private Securities Litigation Reform Act of 1995 (PSLRA), which statements may be identified by words such as “expects,” “plans,” “projects,” “will,” “may,” “anticipates,” “believes,” “should,” “intends,” “estimates,” and other words of similar meaning, including statements regarding expected benefits of the 4Kscore, whether the 4Kscore will accurately identify men more likely to develop distant prostate cancer metastases, whether the 4Kscore will improve long-term prediction of distant prostate cancer metastasis, the power of the 4Kscore to provide valuable information to accurately identify aggressive prostate cancer, including in higher risk populations, and guide clinical decision making, whether it will accurately predict high-grade cancers, whether it will reduce unnecessary biopsies by at least 25%, whether OPKO will successfully commercialize the 4Kscore, and the market for and expected sales of 4Kscore, as well as other non-historical statements about our expectations, beliefs or intentions regarding our business, technologies and products, financial condition, strategies or prospects. Many factors could cause our actual activities or results to differ materially from the activities and results anticipated in forward-looking statements. These factors include those described in our filings with the Securities and Exchange Commission, as well as the risks inherent in funding, developing and obtaining regulatory approvals of new, commercially-viable and competitive products and treatments. In addition, forward-looking statements may also be adversely affected by general market factors, competitive product development, product availability, federal and state regulations and legislation, the regulatory process for new products and indications, manufacturing issues that may arise, patent positions and litigation, among other factors. The forward-looking statements contained in this press release speak only as of the date the statements were made, and we do not undertake any obligation to update forward-looking statements. We intend that all forward-looking statements be subject to the safe-harbor provisions of the PSLRA.

Share on StockTwits